Speakers and Panelists

Boardman, Dr. Anthony,
Member, Patented Medicine Prices Review Board
Brady, Bruce,
Canadian Coordinating Office for Health Technology Assessment
Caulfield, Tim,
Canada Research Chair in Health Law and Policy; Associate Professor, Faculty of Law and Faculty of Medicine and Dentistry; Research Director, Health Law Institute, University of Alberta
Chiles, Vernon,
Vice Chair of the Board, Green Shield Canada
Corvari, Ronald J.,
Director, Policy and Economic Analysis, PMPRB
Decter, Michael B.,
Chairman, Canadian Institute for Health Information
Elgie, Dr. Robert G.,
Chairperson, Patented Medicine Prices Review Board
Elston, Murray,
President, Canada's Research-Based Pharmaceutical
Companies of Canada (Rx&D)
Flood, Colleen,
Professor, Faculty of Law, University of Toronto
Hubbard, Eleanor,
Director, Pharmaceutical Services, Nova Scotia Department of Health
Jacobzone, Stéphane
OECD Health Project
Kanavos, Panos,
Lecturer in International Health Policy, LSE Health and Social Care, UK
Keon, Jim,
President, Canadian Drug Manufacturers Association (CDMA)
Laupacis, Dr. Andreas,
President and Chief Executive Officer,
Institute for Clinical Evaluative Sciences (ICES)
LeLorier, Jacques,
Professor, Depts of Medicine and Pharmacology, Faculty of Medicine, University of Montreal; Adjunct professor, Dept. of Epidemiology and Biostatistics, Faculty of Medicine, McGill University; Chief, Pharmacoepidemiology and Pharmacoeconomy Research Unit Research Centre, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu
Lievonen, J. Mark,
President, Aventis Pasteur Limited
MacLeod, Stuart,
Professor, Clinical Epidemiology and Biostatistics,
Pediatrics and Medicine, McMaster University
McCool, Terry,
Vice President, Corporate Affairs, Eli Lilly Canada Inc.
McMurtry, Robert Y.,
Special Advisor to the Commissioner,
Commission on the Future of Health Care in Canada
Morgan, Steve,
Centre for Health Services and Policy Research, University of British Columbia
Poston, Dr. Jeffrey,
Executive Director, Canadian Pharmacists Association
Rawlins, Sir Michael,
Chairman, National Institute for Clinical Excellence, UK
Sansom, Professor Lloyd,
Chair, Pharmaceutical Benefits Advisory Committee, Australia
Shea, Barbara,
Executive Director, Drug Plan and Extended Benefits, Saskatchewan Health
Shugart, Ian,
Assistant Deputy Minister, Health Policy and Communications, Health Canada
Sketris, Dr. Ingrid,
Member, Patented Medicine Prices Review Board
Sureau, Réal,
Vice-Chairperson, Patented Medicine Prices Review Board
Tennant, Linda
Tholl, William G.,
Secretary General and Chief Executive Officer
Canadian Medical Association
Willison, Don,
Assistant Professor, Department of Clinical Epidemiology and Biostatistics,
McMaster University

Anthony Boardman, B.A., Ph.D.
Member, Patented Medicine Prices Review Board

Dr. Boardman was appointed Member of the Board in January 1999.

Dr. Boardman is the Van Dusen Professor of Business Administration in the Strategy and Business Economics Division, Faculty of Commerce and Business Administration at the University of British Columbia (UBC). He graduated from the University of Kent at Canterbury, England, (B.A., 1970) and Carnegie-Mellon University (Ph.D., 1975). Prior to taking up his position at UBC he was a professor at the Wharton School, University of Pennsylvania. Dr. Boardman's current research interests include privatization, cost-benefit analysis and strategic management. During his career, he has published many articles in leading academic journals. Recently, he completed the second edition of Cost-Benefit Analysis: Concepts and Practice. Dr. Boardman has been a consultant to many private and public organizations, including Vodafone, Stora Enzo, PriceWaterhouse Coopers, the Treasury of New Zealand and all levels of government in Canada. He is also an excellent teacher and has taught executive programmes in Finland, China, Australia and elsewhere. As a member of the MBA Core Team at UBC, he recently won the Alan Blizzard award. Between 1995 and 2001, Dr. Boardman was a member of the Pharmacoeconomic Initiative Scientific Committee which made recommendations to B.C. Pharmacare on the cost-effectiveness of new drugs.

Bruce Brady
Canadian Coordinating Office for Health Technology Assessment
( http://www.ccohta.ca )

About CCOHTA

CCOHTA is a non-profit corporation funded by the federal, provincial and territorial ministers of health.

CCOHTA's function is to provide evidence-based information on emerging and existing health technologies, primarily to Canadian health care policy makers and managers.
'Technologies' is broadly defined as any medical procedures, devices, systems or drugs used in the maintenance, treatment and promotion of health.

Mandate

CCOHTA's mission is to encourage the appropriate use of health technology by influencing decision makers through the collection, analysis, creation and dissemination of information concerning the effectiveness and cost of technology and its impact on health.

As a national organization, we aim to facilitate information exchange, resource pooling and the coordination of priorities for health technology assessments.

Timothy A. Caulfield, B.Sc., LL.M.
Canada Research Chair in Health Law and Policy;
Associate Professor, Faculty of Law and Faculty of Medicine and Dentistry;
and Research Director, Health Law Institute, University of Alberta

Timothy Caulfield has been Research Director of the Health Law Institute at the University of Alberta, since 1993. He recently received a Canada Research Chair in Health Law and Policy. He is also an Associate Professor in the Faculty of Law and the Faculty of Medicine and Dentistry. His research has focussed on two general areas: genetics, ethics and the law; and the legal implications of health care reform in Canada. Over the past several years he has been involved in a variety of interdisciplinary research endeavours which have allowed him to publish numerous health law articles and book chapters. He is the recipient of an Alberta Heritage Foundation for Medical Research Health Research Scholarship entitled "Regulating the ‘Genetic Revolution;'" an Alberta Law Foundation funded project on Health Care Reform in Alberta; a Genome Canada project on the regulation of genomic technologies and is an associated theme leader in the recently created Stem Cell Network (National Centres of Excellence). He was recently a visiting scholar at the Hasting Center for Bioethics in New York, and has been a Visiting Fellow at Stanford University's Program in Genomics, Ethics and Society and is a Senior Fellow with the Einstein Institute for Science, Health and the Courts. In November 2000, he was awarded the University of Alberta's Martha Cook Piper Research Prize. Professor Caulfield is a member of the Canadian Biotechnology Advisory Committee; The Health Canada's Expert Advisory Committee on Xenograft Regulation; the Royal Society of Canada's Expert Panel on the Future of Food Biotechnology (2001); and the Institute Advisory Board, Institute of Health Services and Policy Research, Canadian Institute of Health Research. He also serves on a number of research ethics boards, is an editor of the Health Law Journal and the Health Law Review, teaches Law and Medicine in the Faculty of Law, and provides health law lectures for other faculties.

Vernon Chiles, Vice Chair of the Board, Green Shield Canada

Mr. Chiles has served as pharmacy benefits consultant and editor of Green Shield's Analysis of Drug Claims Costs 1997-2001. His background is in community pharmacy in Sarnia, Ontario where he edited a monthly therapeutics newsletter for health care providers from 1966 to 1995. He has served in numerous roles with professional organization such as the Canadian Pharmacists Association and the Ontario Pharmacists Association and with government agencies such as Ontario's Drug Quality and Therapeutics Committee, the Ontario Drug Programs Reform Secretariat, the Therapeutic Products Directorate, and the Patented Medicine Prices Review Board.

Green Shield Canada is a not-for-profit private sector health claims administrator.

Ronald J. Corvari, Director, Policy and Economics Branch,
Patented Medicine Prices Review Board

Ron Corvari is responsible for policy analysis and development, consultation, economic research and studies at the PMPRB. Dr. Corvari manages a policy and economics staff.

Prior to taking on his current role with the PMPRB, Dr. Corvari served as research economist and analyst with the Economic Council of Canada, the MacDonald Royal Commission on the Canadian Economy and was Economics Instructor at Carleton University.

He graduated from Guelph University (B.A. (Hons) in Economics) and Carleton University (M.A. and Doctorate of Philosophy in Economics - specialization in Industrial Organization and International Economics).

Michael B. Decter, Chairman, Canadian Institute for Health Information

Michael B. Decter is a Harvard trained economist with over two decades of experience as a senior manager. He is a leading Canadian expert on health systems, with a wealth of international experience.

As a senior manager in the public sector, Michael served as Deputy Minister of Health for Ontario with responsibility for the management of the $18 billion Ontario health system serving 11 million residents of the province. He also served as Cabinet Secretary in the Government of Manitoba.

As Senior Research Scholar at the Centre for Bioethics, University of Toronto, Michael Decter authored the book: Healing Medicare: Managing Health System Change – The Canadian Way, published in 1994. His second health book, Four Strong Winds – Understanding the Growing Challenges to Health Care, was published in June, 2000. Michael Decter was an International Fellow of the King's Fund in London, England.

Michael has also authored two additional books, Michael Decter's Million Dollar Strategy (1998), and The DRIP Strategy: Building your Wealth one share at a time with Dividend Reinvestment plans (2001).

As a public speaker on health policy and reform, Michael has addressed audiences across Canada, in the United States, the United Kingdom, Germany, Italy, and the Netherlands. In 1995, Michael Decter chaired the Four Country Conference in Amsterdam, The Netherlands which brought together experts from Canada, the United States, Germany and Holland. In 1996, he undertook a major speaking tour in Australia.

As a consultant, Michael has lead major assignments for many of Canada's leading teaching hospitals. These assignments have included reengineering, mergers, and strategic planning. Hospitals and health systems among Michael's clients have included the Toronto Hospital, Capital Health Authority, St. Boniface General Hospital, Chedoke McMaster Health Sciences Centre, St. Michael's Hospital, and the Capital Health Authority in Edmonton. Consulting positions have included Partner at KPMG, and Managing Director - Canada for APM/CSC.

Michael Decter has also worked for health associations and for religious orders with works in the health field. Clients have included the Catholic Health Association of Canada, Les Soeurs de la Charité de Montréal, the Grey Nuns of Manitoba, and the Catholic Health Association of Ontario.

As a negotiator and facilitator, Michael has represented governments, corporations, and hospitals. In negotiations such as the 1991 Framework Agreement between the Ontario Government and the Ontario Medical Association, Michael has achieved consensus where parties are far apart. Michael facilitated the merger of the Etobicoke, Peel Memorial, and Georgetown District Hospitals. As well, he facilitated programme transfers between the Toronto Hospital and Mount Sinai Hospital. In these instances, he worked jointly for the hospitals involved at the request of their boards and CEO's.

Michael Decter remains active as a facilitator and public speaker as Managing Director of Michael Decter and Associates Ltd. He also serves as President of the investment management firm, Lawrence Decter Investment Counsel Inc.

Michael is also the Chair of the Canadian Institute for Health Information, as well as a Board Member of Interhealth Canada Ltd., Assessment Strategies Inc., Lawrence Decter Investment Counsel Inc., and The Public Policy Forum.

Robert Goldwin Elgie, LL.B., M.D., F.R.C.S.(C), LL.D. (hon.)
Chairperson of the Patented Medicine Prices Review Board, Canada

Robert Goldwin Elgie was appointed Chairperson of the PMPRB in March 1995 and re-appointed in March 2000.

Dr. Elgie, a lawyer and neurosurgeon, was the founder and first Director of Dalhousie University's Health Law Institute from 1991 to 1996. He was also the part-time Chair of the Workers' Compensation Board of Nova Scotia from 1992 to 1996.

He is a graduate of the University of Western Ontario (B.A., 1950), Osgoode Hall Law School (LL.B.); the University of Ottawa, Faculty of Medicine (M.D., 1959); and, upon completion of his training in neurosurgery at the University of Toronto, he became a Fellow of the Royal College of Surgeons (Neurosurgery) in 1966.

Dr. Elgie has taught at the Medical Schools of Queen's University and the University of Toronto and has held several positions with the Scarborough General Hospital, including Chief of Medical Staff.

In 1977, he was elected to the Ontario Legislative Assembly as the Member for York East. He served as Parliamentary Assistant to the Minister of Community and Social Services and, subsequently, he served as Minister of Labour; Minister of Consumer and Commercial Relations; and Minister of Community and Social Services. He resigned from the Ontario Legislature in September 1985 to become Chair of the Workers' Compensation Board of Ontario where he served until 1991.

In October 2000, Dr. Elgie was appointed to the Ontario Press Council. In May 2001, he was awarded an honorary degree by Dalhousie University: Doctor of Laws, honoris causa, in recognition of his outstanding personal achievements.

Dr. Elgie is married to Nancy Anne Elgie (nee Stewart), a child psychologist. They have three sons, two daughters, nine grandchildren and one dog.

Murray Elston, Rx&D's President

On November 1, 1998 Mr. Elston was appointed President of Canada's Research-Based Pharmaceutical Companies (Rx&D).

From January to October 1998, Mr. Elston was a member of the Energreen Solutions Group and from 1994 to 1997 served as President of the Ontario Interlink Industrial Park.

From 1981 to 1994 Mr. Elston served as a member of the Ontario Legislature where he held a number of positions including Minister of Health, Chairman of the Management Board, Minister of Financial Institutions and Chairman of the Public Accounts Committee.

Mr. Elston is a graduate of the University of Western Ontario and holds a Bachelor of Arts and a Bachelor of Law degree. Prior to being elected to the Ontario Legislature, Mr. Elston practiced law in Bruce County, Ontario.

Mr. Elston is a Director of the International Federation of Pharmaceutical Manufacturers Association (IFPMA). He also is a member on the Boards of Directors of the Canadian Nurses Foundation (CNF), the Canadian Medical Hall of Fame (CMHF), the Institute of Mental Health Research (IMHR), HydroOne and former Board member of the Canadian Network for Vaccines and Immonotherapeutics for Cancer and Chronic Viral Diseases (CANVAC).

Mr. Elston has been a member of the Board of Directors at the General Insurance Company of The Royal Bank of Canada since 1997.

Rx&D represents member companies of the research-based innovative pharmaceutical industry in Canada.

Colleen M. Flood, Faculty of Law, University of Toronto
( http://www.law.utoronto.ca )

Eleanor Hubbard, PhC
Director, Pharmaceutical Services, Nova Scotia Department of Health

Eleanor Hubbard has approximately twenty years experience in health care. She has worked in management positions within retail pharmacy, the private insurance industry, and as a consultant, prior to moving to the public sector where she has provided leadership and vision for pharmaceutical services for Nova Scotians for more than ten years.

Ms. Hubbard is responsible for policy and program development, standards development, implementation, administration and evaluation of the Nova Scotia Seniors' Pharmacare Program, Department of Community Services Pharmacare Program, Special Disease Programs, and Hospital and High Cost Drug Programs. She and her team provide policy advice and strategic direction on pharmaceutical issues to Home Care, Long Term Care, Primary Health Care, District Health Authorities, and Hospitals.

Ms. Hubbard has served on numerous committees including the Federal/Provincial/
Territorial (F/P/T) Ministers' Working Group on National Pharmacare, F/P/T Ministers' Task Force on Prices, Utilization and Marketing of Pharmaceuticals, Task Force on the National Drug Formulary Service, National Working Group on HIV/AIDS Medications, Steering Committee for Guidelines for the Economic Evaluation of Pharmaceuticals in Canada, Nova Scotia Population Health Research Unit Advisory Committee, Family Violence Prevention Initiative and Women's Health Issues. She is past Co-Chair of the F/P/T Pharmaceutical Issues Committee and currently serves as Chair of the Canadian Coordinating Office for Health Technology Assessment.

Stéphane Jacobzone, OECD Health Project

Mr. Jacobzone is a graduate of École Polytechnique and l'École nationale de la statistique et de l'amdministration économique (ENSAE), and has worked as an economist for the French government, l'Institut national de la statistique et des études économiques - Conseil de la recherche scientifique et technique (INSEE-CREST), the Ministry of Finance and the French Planning Agency, specializing in health and public economics.

His previous French health economics experience include drug pricing issues, hospital efficiency, health insurance design, the analysis of preventive behaviours and supply-induced demand. He has also worked on social issues such as analyzing the impact of the European Union on the French welfare state, forecasting French social accounts, auditing the French minimum income scheme, and discussing public sector issues such as the deregulation of French public utilities.

Since joining the OECD in 1997, he has worked on ageing and health related issues, trends in disability among older populations and their implications for health and long-term care policies, pharmaceutical policy, informal care-giving and long-term care systems, and trends in health expenditure by age. He has led a study on measuring the performance of health care systems in the treatment of Ageing-related Diseases (Ischaemic Heart Disease, Breast Cancer, Stroke). He has also been involved in a study on pharmaceutical consumption across 12 OECD countries for cardiovascular disease and further work in the field.

He is now in charge of coordinating the new OECD Health Project, which is an initiative of the OECD to tackle health as a multidimensional issue. Further projects that he is currently involved in include a study of human resources for health care systems and the measurement of equity.

Panos Kanavos, Lecturer in International Health Policy,
LSE Health and Social Care, UK

Panos Kanavos is lecturer in International Health Policy and course coordinator for the MSc in International Health Policy within the department of Social Policy.

His research interests comprise:

the economics of health-related high technology industries
health system analysis form an international perspective
health and pharmaceutical system reform from an international perspective.

He is currently coordinating:

the database on European Pharmaceutical policies, a project sponsored by the European Commission – DG Enterprise.
The Clearinghouse/Database on Pharmaceutical Economics & Policy at the London School of Economics (LSE Health), a project sponsored by the World Health Organization – Europe Office.

He has acted as advisor to the World Health Organization and the World Bank on a number of missions related to the following areas:

Pharmaceutical sector reform in the Philippines
Global Generic Pharmaceutical Policies
Pricing and reimbursement of pharmaceuticals in Bulgaria
Pharmacy privatization in Former Yugoslav Republic of Macedonia
Development of Training materials in Health Economics; Health Forum on Technology Assessment in Health Care
Pharmaceutical Economics & Policy with Application to Eastern Europe
European Health Care Reform; Macroeconomic & Health Constraints in Health Systems Reform

Jim Keon, President, Canadian Drug Manufacturers Association

Jim Keon is President of the Canadian Drug Manufacturers Association (CDMA), the organization representing Canada's generic pharmaceutical industry.

Under his leadership, the CDMA works closely with all levels of government to develop policies to nurture and grow Canada's drug industry both in Canada and for export markets. To achieve this, Jim advocates for fair and balanced patent laws, which ensure the timely availability of generic drugs for Canadians. He also works closely with provincial governments to help them control soaring drug costs through the more efficient listing of generic medicines on provincial drug plan formularies.

Mr. Keon graduated with an M.A. in Economics from Queen's University, and has extensive experience in areas of intellectual property, trade and consumer protection. Prior to joining CDMA in 1994 (he became President in 1998) he held senior positions in the federal government and was directly involved in international trade negotiations for the FTA, NAFTA and the WTO, as well as Canada's inter-provincial trade negotiations. He is co-Director of the International Generic Pharmaceutical Alliance (IGPA).

The Canadian Drug Manufacturers Association's 19 member companies specialize in the production of high quality, affordable generic pharmaceuticals, fine chemicals and new chemical entities. The industry plays a vital role in Canada's health care system by providing safe, proven alternatives to more expensive brand name prescription drugs. The use of generic pharmaceuticals saves Canada's health care system $1.4 billion annually.

Andreas Laupacis, MD, MSc, FRCTC
President and Chief Executive Officer, Institute for Clinical Evaluative Sciences (ICES)

Dr. Laupacis is a General Internist. In September 2000, he became President and Chief Executive Officer of the Institute for Clinical Evaluative Sciences (ICES) in Toronto and a Professor in the Department of Medicine at the University of Toronto.

Prior to assuming his position at ICES, he was the first Director of the clinical Epidemiology Unit at the Loeb Health Research Institute at the Ottawa Hospital. He was also a Professor in the Departments of Medicine and Epidemiology and Community Medicine, University of Ottawa and Vice Chair (Research) of the Department of Medicines, University of Ottawa.

Dr. Laupacis received his medical degree from Queen's University. He did his internship at Dalhousie and residence in internal medicine at the University of Western Ontario.

His research training included two years as a Medical Research Council of Canada (MRC) Research Fellow with Dr. Calvin Stiller at the University of Western Ontario studying the efficacy of cyclosporine as an immunosuppressant in transplantation and diabetes. He also has a Masters degree in Design, Measurement and Evaluation from McMaster University. He taught at the University of Western Ontario for five years before moving to the University of Ottawa in 1991.

Dr. Laupacis' initial research interests were in the design and execution of multi-centre clinical trials, evaluating methods of presenting the results of clinical trials to patients and clinicians, and health care technology assessment. More recently, he has become involved in the areas of pharmacoeconomics, drug policy and the use of diagnostic tests.

Dr. Laupacis was the first recipient of a Fellowship of the International Society of Technology Assessment in Health Care (ISTAHC), and later served on its Board and as Treasurer. He is a member of numerous committees, including the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health. He has published over 150 articles in peer-reviewed journals and is a Senior Scientist of the Canadian Institutes of Health Research.

Dr. Jacques LeLorier, MD, PhD, FRCPC
Professor, Departments of Medicine and Pharmacology,
Faculty of Medicine, University of Montreal;
Adjunct professor, Dept. Epidemiology and Biostatistics,
Faculty of Medicine, McGill University; and,
Chief, Pharmacoepidemiology and Pharmacoeconomy Research Unit
Research Centre, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu

Dr. Jacques LeLorier was born in Mexico where he got his medical degree at the University of Mexico. He spent 7 years in Minnesota where he obtained a PhD in Pharmacology and Biostatistics and completed a residency in internal medicine.

He then moved to Montreal where he became assistant director of the clinical pharmacology department at Ayerst Laboratories. In 1974, he became member of the pharmacology department of the faculty of medicine of the University of Montreal and of the department of medicine of the Hôtel-Dieu de Montréal hospital. He founded the medical obstetrics department at Sainte-Justine hospital and the service of Clinical Pharmacology at the Hôtel-Dieu de Montréal hospital.

From 1985 to 1991, he chaired the departments of medicine of the Hôtel-Dieu de Montréal hospital and of the faculty of medicine of the University of Montreal. In 1979, he became member, and from 1987 to 1996, president of the Advisory Council on Drugs of the Ministry of Health of the Quebec government.

Since January 1993, he is the head of the Pharmacoepidemiology and Pharmacoeconomy Research Unit at the Research Centre of the Hôtel-Dieu de Montréal Hospital.

Since 1996, he directs the clinical pharmacology program at the University of Montreal.

He is a member of the Honorary Editorial Board of Journal of Clinical Epidemiology, Disease Management & Health Outcomes and Journal of Evaluation in Clinical Practice.

In 1998 he became Director, and in August 2000 President-Elect of the International Society of Pharmaco-Epidemiology.

His main research interests are pharmacoepidemiology and pharmacoeconomics.

J. Mark Lievonen
President, Aventis Pasteur Limited, (formerly Pasteur Mérieux Connaught)

J. Mark Lievonen is President of Aventis Pasteur Limited. He is responsible for all of the company's operations in Canada and is a member of Aventis Pasteur's global market process team and its North American Management committee.

Mr. Lievonen has been with the company for 18 years. He started in the treasury department and was promoted to Corporate Vice President, Finance, in 1988. Since 1990, Mr. Lievonen has held a number of senior management positions, and has been responsible for the company's overall commercial operations. His responsibilities included overseeing Aventis Pasteur's activities in Mexico from 1992 to 1999.

Prior to his appointment as President, Mr. Lievonen was Senior Vice President and General Manager of the Oncology Business Unit. He was responsible for the strategy and funding of Aventis Pasteur's cancer vaccine program and the global marketing and sales of cancer immunotherapeutic products.

Mr. Lievonen holds a Bachelor's and a Master of Business Administration degree from York University. He received his Chartered Accountant designation in 1981 while working with Coopers & Lybrand.

Mr. Lievonen is the Chairman of the Board of Directors of BIOTECanada and also Chairman of the Steering Committee of the BIO2002 Conference held in Toronto in June 2002. He is a member of the Ontario Government's BIOCouncil, a group whose mandate is to provide strategic advice necessary to help the province become the third-largest jurisdiction for biotechnology in North America. He served as a member of the Canadian Liver Foundation's Board of Directors from 1995 to 1998 and as a Business Ambassador of the Government of Ontario. He was also a member of the 1998 Ontario Biotechnology Task Force.

Aventis S.A. (NYSE:AVE) is a world leader in life sciences. Focused on two core business areas - pharmaceuticals and agriculture - Aventis is dedicated to improving life through the discovery and development of innovative products in the fields of prescription drugs, vaccines, therapeutic proteins, crop production and protection, animal health and nutrition. With global corporate headquarters in Strasbourg, France, Aventis employs around 90,000 people in 150 countries and recorded pro forma sales in 1998 of euros 21 billion (US$ 21.3 billion).

Stuart MacLeod, BSc (Meds), MD, PhD, FRCPCP, FRCP (Glas), FRCP (Edm)
Professor, Clinical Epidemiology and Biostatistics, Pediatrics and Medicine,
McMaster University

Dr. MacLeod is a member of the Centre for Evaluation of Medicines.

Dr. MacLeod received his MD from the University of Toronto in 1967 and completed postgraduate training in Internal Medicine (clinical pharmacology) at McGill University and the Montreal General Hospital. He obtained a PhD in Pharmacology from McGill in 1972. From 1973 until 1986, he occupied various positions at the University of Toronto and its teaching hospitals. At the time of his departure from Toronto in December 1986, Dr. MacLeod was a Professor of Pharmacology, Clinical Biochemistry, Medicine, Pharmacy, and Pediatrics, and was cross-appointed to the Faculty of Pharmacy. He was the Director of the Division of Clinical Pharmacology at The Hospital for Sick Children.

Dr. MacLeod was the Founding Director of the Father Sean O'Sullivan Research Centre from 1992 to July 1, 2002. In the period 1987 through March 1992, Dr. MacLeod served as Dean of the Faculty of Health Sciences at McMaster University. Dr. MacLeod has been a member or chair of numerous grant review panels for the Medical Research Council of Canada, Canadian Heart and Stroke Foundation, Hospital for Sick Children Foundation, the Arthritis Society, the National Institutes of Health (USA), and the Ontario Health Innovations Fund. He currently serves as Chairman of the Canadian Medical Association Committee on Publications, Communications and Professional Development, and the Canadian Pediatric Society Committee on Drugs and Hazardous Substances.

He is a member of the Drug Utilization Advisory Committee for the Ontario Ministry of Health and Long-Term Care and also chairs a Tripartite Committee (OMA, OPA, MOHLTC) on Limited Use (LU) Drugs in Ontario, and a Working Group on Pediatric Services in Community Hospitals.

For the Federal Government, Dr. MacLeod is a member of the Therapeutic Products Program Advisory Committee on Management and the Science Advisory Board for Health Canada. He co-chairs a Steering Committee on antenatal drug risk surveillance (Mothernet).

Dr. MacLeod is also Vice President for Medical Affairs at Innovus Research Inc., a Canadian-based international CRO, headquartered in Burlington, Ontario with offices in Boston and the UK.

Dr. MacLeod's scientific interests are in improved understanding of the determinants of drug disposition and action. His concerns embrace the multitude of factors that influence optimal therapeutic drug use. He has authored or co-authored more than 200 medical papers, book chapters, and books in his areas of specialty. A second edition of this book, Pediatric Pharmacology and Therapeutics, appeared in 1993.

At the international level, Dr. MacLeod has taught with and coordinated several projects in Africa. He has worked with a number of international agencies and institutions including the Canadian International Development Research Centre, and the Rockefeller Foundation. A sabbatical year in 1993 was spent at the London School of Hygiene and Tropical Medicine.

Terry McCool, Vice President, Corporate Affairs, Eli Lilly Canada Inc.

D. Terry McCool is the Vice President of Corporate Affairs at Eli Lilly Canada. In this role he is responsible for all aspects of corporate affairs including federal and provincial government affairs, policy development, pricing, health economics, communications and public affairs.

He is a member of the Senior Management Team and the Board of Directors of Eli Lilly Canada. Mr. McCool is also a Board Member of the Institute of Health Economics.

Since joining Eli Lilly Canada in 1971, Mr. McCool has held various senior management positions including Director of Sales and Director of Human Resources.

Mr. McCool earned a Bachelor of Science in Pharmacy from the University of Alberta.

Robert Y. McMurtry, Special Advisor to the Commissioner,
Commission on the Future of Health Care in Canada

Dr. McMurtry joined Health Canada in 1999 as the first G.D.W. Cameron Visiting Chair. In this capacity he was charged with providing advice to the Deputy Minister on issues of a scientific nature, and acted as a liaison between Health Canada and the scientific community at large.

Dr. McMurtry was later appointed the Assistant Deputy Minister of the Population and Public Health Branch, Health Canada. In this capacity, Dr. McMurtry was responsible for a broad spectrum of issues which collectively support health promotion and disease control and prevention programs aimed at improving the physical, mental and emotional well-being of Canadians.

Prior to joining Health Canada, Dr. McMurtry gained considerable experience in several areas of the health care field. Early in his career he served abroad, spending two years in Africa, mainly at a mission hospital. Upon his return to Canada, he specialized in orthopaedic and hand surgery, and founded and directed Sunnybrook Medical Centre's trauma unit, as well as a multi disciplinary hand surgery unit.

In 1988, he joined the University of Calgary as Professor and Head of Surgery. He also held the position of Head of Surgery for Foothills Hospital until he was appointed, in 1992, to the position of Dean of the Faculty of Medicine (now the Faculty of Medicine and Dentistry) at the University of Western Ontario.

He has served on many advisory boards and committees, including the Medical Research Council and the Interim Governing Council for the Canadian Institutes of Health Research (CIHR). In 1994-95, he chaired an Ontario provincial committee on the role, function and financing of academic health science centres, and in 1995 he conducted a review of the Provincial Cancer Network. Dr. McMurtry was an ex-officio member of Health Canada's Science Advisory Board and is currently an Institute Advisory Board member of CIHR's Institute of Musculoskeletal Health and Arthritis.

Dr. McMurtry has published widely in his areas of interest. Included among his many research interests are trauma, the biomechanics of the wrist and health systems and services.

Steve Morgan, Centre for Health Services and Policy Research,
University of British Columbia

Steve Morgan is a Canadian Institutes of Health Research post-doctoral Fellow in health economics at the UBC Center for Health Services and Policy Research. His research focuses on a wide range of pharmaceutical policy issues, including the determinants of pharmaceutical expenditure growth, pharmaceutical insurance programs, and issues surrounding the financing of and priority setting for new health care technologies. He has published work on pharmaceutical policy and health economics, and is a consultant to federal and provincial governments in Canada.

Dr. Morgan obtained a BA (Hon.) in economics at the University of Western Ontario, an MA in economics at Queen's University, and a Ph.D. in economics at the University of British Columbia.

Jeffrey Poston, B.Pharm., PhD MRPharmS.
Executive Director, Canadian Pharmacists Association (CPhA)

Jeff Poston was appointed Executive Director of the Canadian Pharmacists Association (CPhA) in June 1999, following a successful tenure as Director of Research and Practice Development. A hallmark of Dr. Poston's career has been a commitment to innovation, pioneering innovative approaches to developing the role of the pharmacist. As a teacher, he developed new undergraduate and postgraduate pharmacy programs and was one of the early group of pharmacists who developed expertise in health services research. His experience at CPhA has been very broad encompassing the development of health services research relevant to the pharmacists' role in health care; the development of practice tools and guidelines to enhance practice; the creation of policy documents to support advocacy initiatives; and the advancement of technology relevant to pharmacy practice. He has actively contributed to the formation and work of national coalitions on managed care and pharmacare, the Community Pharmacy Economics Committee, and the development and financing of the Pharmacy Electronic Communication Standard.

In his role as CPhA's new Executive Director, Dr. Poston sees a number of challenges. Drug costs are likely to continue to escalate bringing new pressures for cost-containment. New drug technology, information technology, the advent of Internet pharmacy, reform of health care and continuing developments in retail distribution and competition will create a vast array of threats and opportunities for pharmacy.
Dr. Poston is confident that CPhA's Board has the necessary vision and leadership to respond to these challenges.

Jeff Poston obtained his bachelor of pharmacy degree and a PhD in pharmacy from the University of Wales in Britain. He has broad experience in pharmacy having worked in hospital, industry and community practice. For 12 years, he held an academic position in a Faculty of Pharmacy. He is a member of several national and international organizations in pharmacy, health economics and health services research.

Sir Michael Rawlins
Chairman, National Institute for Clinical Excellence, UK

Sir Michael has been Professor of Clinical Pharmacology at the University of Newcastle since 1973. He is also a Consultant Physician and Clinical Pharmacologist at the Freeman Hospital and at the Royal Victoria Infirmary in Newcastle upon Tyne. Sir Michael was Chair of the Committee on Safety of Medicines from 1993 to 1998 and was previously a Committee Member for 14 years. He is Chair of the Advisory Council on the Misuse of Drugs and Director of the WHO Collaborating Centre for Drug Policy and Drug Safety Research. He was appointed Chairman of the National Institute for Clinical Excellence in November 1998.

Professor Lloyd Sansom
AO, Chair, Pharmaceutical Benefits Advisory Committee, Australia

Professor Sansom was appointed the Chair of the Pharmaceutical Benefits Advisory Committee in January 2001 having been the Chair of the Australian Pharmaceutical Advisory Council since 1991. Professor Sansom has been involved in the development of Australia's National Medicines Policy and has been a member of the Pharmaceutical Sub-Committee of ADEC for many years. He holds the title of Emeritus Professor at the University of South Australia. His research interests are in the areas of pharmacokinetics, biopharmaceutics and the Quality Use of Medicines.

Professor Sansom was appointed an Officer of the Order of Australia in June 2002.

Barbara Shea, Executive Director,
Drug Plan and Extended Benefits, Saskatchewan Health

Barb Shea's professional life has always been connected, in some way to the management of pharmaceuticals. Her experience ranges from front line service as a practicing pharmacist, to pharmacy owner, to involvement in local, provincial, national and international pharmacy organizations to private consulting and now, to public service.

Barb has served as Executive Director, Drug Plan and Extended Benefits Branch at Saskatchewan Health since 1992. Working with a talented and dedicated team, the Branch provides policy analysis, program development and program delivery for several province wide programs for the people of Saskatchewan. These programs include extended health benefits such as dental, optometric, and chiropractic services to families with low incomes. Other provincial programs include home oxygen, orthopedic services and mobility aids. In this role, she is responsible for staff of 45 and an annual program budget of $168 million.

Barb has served on several committees related to the profession of pharmacy and more recently on Federal/Provincial/Territorial committees related to publicly funded drug programs and strategies for the management of pharmaceuticals. She has been president of both the Saskatchewan Pharmaceutical Association (SPhA) and the Canadian Pharmacists Association (CPhA). She is currently co-chair of the Federal/Provincial/Territorial Pharmaceutical Issues Committee.

Outside of the contributions Barb is able to make in her work life, she is planning on breaking 80 in golf next season.

Ian Shugart, Assistant Deputy Minister,
Health Policy and Communications, Health Canada

Ian Shugart is the Assistant Deputy Minister, Health Policy and Communications Branch. Previously, he was the Visiting Assistant Deputy Minister in the Health Protection Branch of Health Canada, responsible for the coordination of the HPB Transition project. This project was created to position the Health Protection Branch to meet the needs of Canadians for health risk management in the next century.

Mr. Shugart was the Executive Director of the former Medical Research Council for four years. He previously served as Assistant Secretary to the Cabinet for Social Policy and Programs in the Federal Provincial Relations Office of the Privy Council Office. He was Chief of Staff to the Minister of Energy, Mines and Resources. He also spent four years in the Department of National Health and Welfare as the senior advisor on policy matters to the Minister. He studied Political Economy at Trinity College, University of Toronto.

Ingrid S. Sketris, BSc(Phm), Pharm.D., MPA(HAS)
Member, Patented Medicine Prices Review Board

Dr. Sketris was appointed Member of the Board in May 1999.

Dr. Sketris is a Professor at the College of Pharmacy and School of Health Services Administration and an Associate Professor of the Department of Community Health and Epidemiology, Dalhousie University. She is a consultant to the pharmacy department of the Queen Elizabeth II Health Sciences Centre, Halifax. Since 2000, Dr. Sketris holds a Chair in health services and nursing from the Canadian Health Services Research Foundation/Canadian Institutes of Health Research (Cosponsored by the Nova Scotia Health Research Foundation). She is a graduate of the University of Toronto (BSc(Phm), 1977), University of Minnesota (Pharm.D,1979), University of Tennessee Center for the Health Sciences (Residency in Clinical Toxicology/Pharmacy Practice, 1980) and Dalhousie University (MPA(HSA) 1989). She is a fellow of the Canadian Society of Hospital Pharmacists and the American College of Clinical Pharmacy.

Dr. Sketris is currently on the Editorial Boards of the Canadian Journal of Clinical Pharmacology, Clinical Therapeutics, and Drugs and Therapeutics for Maritime Practitioners. She was a member of the scientific advisory panel of the Canadian Coordinating Office for Health Technology Assessment from 1996-1998.

Dr. Sketris' research interests include examining the impact of changes in Pharmacare policy and the use of drugs and health services particularly related to the population of Nova Scotia. She has numerous publications in the area of transplantation therapeutics and pharmacoepidemiology.

Réal Sureau, FCA
Vice-Chairperson, Patented Medicine Prices Review Board

Mr. Sureau was appointed Member and Vice-Chairperson of the Board in October 1995 and re-appointed in October 2000.

A chartered accountant, Mr. Sureau is President of Sureau Management Limited. From January 1997 to February 2000, he was Director of Business Development of the Montréal Baseball Club. From June 1995 to June 1996, he was President of the Order of Chartered Accountants of Québec. Through the years, Mr. Sureau was a member of several committees of the Order, including the Disciplinary Committee, the Professional Practice Committee, the Professional Development Committee and the Committee on Government Finances. He was Vice-President, Finance, at Forex and Canam-Manac.

Mr. Sureau sits on the board of directors of many organizations, including Gaz Métropolitain and the Institut de réadaptation de Montréal.

Linda Tennant

Linda spent thirty years with the Ministry of Health and Long Term Care in Ontario and has extensive policy and program management experience in a variety of areas, including: the Ontario Health Insurance Plan (OHIP), Community Mental Health, Fiscal Strategies, Health Planning and Health Human Resources Planning.

Linda has considerable knowledge of and expertise in drug benefit programs. Until recently, Linda was the Director of the Drug Programs Branch which manages Ontario's publicly funded drug programs, a position she held for six years. In this capacity, Linda led the design and implementation of drug policy and program changes for the province. She worked closely with stakeholder representatives in medicine, nursing and pharmacy, as well as industry and consumer groups. She also worked with colleagues in other provincial, territorial and federal programs.

Linda has a BA in political science from the University of Toronto.

William G. Tholl,
Secretary General and Chief Executive Officer,
Canadian Medical Association

Mr. William Tholl joined the Canadian Medical Association (CMA) as Secretary General and Chief Executive Officer on April 17, 2001. Prior to joining the CMA, Mr. Tholl served as the Executive Director of the Heart and Stroke Foundation of Canada since 1996. He has also held senior executive positions with both the Canadian Medical Association (1990-1995) and Health Canada (1978-1990).

Born and raised in Saskatchewan, Mr. Tholl graduated from the University of Manitoba in 1976 with a graduate degree in health economics. He has held academic appointments as Associate Professor, Queens University (1991-1997) and teaches at both Carleton University and the University of Ottawa in health policy.

Mr. Tholl is a recognized expert consultant, both nationally and internationally, on matters of health finances, health policy and strategic planning and management. His background and expertise have resulted in appointments to several Boards and Committees of health related organizations, including the Canadian Stroke Network, CMA Holdings and the Canadian Medical Foundation.

Don Willison, Assistant Professor,
Department of Clinical Epidemiology and Biostatistics, McMaster University

Don Willison holds a Career Scholar award with the Canadian Institute of Health Research (CIHR), and works out of the Centre for Evaluation of Medicine at
St. Joseph's Healthcare in Hamilton, Ontario.

Currently, his research focuses on two areas:

pharmaceutical policy, and
data privacy issues, as they relate to the secondary use of personal health information for research purposes.

In the area of pharmaceutical policy, Dr. Willison has recently completed a study describing how seven Western countries have balanced pharmaceutical cost-containment with access to needed medications and their interest in attracting or maintaining pharmaceutical R&D in their countries. He has also published recently on challenges associated with the patenting of genetic material and is currently investigating the effects of provincial policies to restrict the reimbursement of newer anti-inflammatory drugs.

Last updated: October 2, 2002